VJHemOnc Podcast The Myeloma Sessions: smoldering myeloma, MRD evaluation, R/R disease & transplant-eligible patients
Jul 3, 2020
Francesca Gay, an expert in multiple myeloma, discusses the latest developments in the field. Topics include high-risk smoldering myeloma, monoclonal antibody treatment, MRD monitoring, T cell engagers and CAR T cells in immunotherapy, and the advantages and limitations of CAR-T cell therapy and bi-specific antibodies.
Chapters
Transcript
Episode notes
1 2 3 4 5 6
Introduction
00:00 • 4min
Challenges and Treatment Approaches for High-Risk Smoldering Myeloma
04:05 • 15min
Combination of Monoclonal Antibody and Dexamethasone in Myeloma Treatment
19:04 • 7min
Standard of Care and MRD Monitoring in Myeloma
26:24 • 11min
Comparison of T cell engagers and CAR T cells in myeloma immunotherapy
36:58 • 2min
Advantages and Limitations of CAR-T Cell Therapy and the Potential of Bi-Specific Antibodies in Treating Myeloma
39:18 • 6min